Tonix Pharmaceuticals (TNXP) stock gains as the company posts peer-reviewed data for pain drug TNX-102 and new data for mpox ...

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) saw its stock rise 2% after unveiling new preclinical findings for its ...

Tonix Pharmaceuticals (NASDAQ: TNXP) , a fully integrated biopharmaceutical company, announced that Dr. Sina Bavari, Executive Vice President of Infe ...

Single dose vaccination with TNX-801 protects animals from a lethal challenge with monkeypox, the causative agent of mpox TNX ...

Market is projected to grow at a CAGR of 5% through 2029, fueled by rising R&D costs, declining pharmaceutical sales, growing ...

Tonix Pharmaceuticals (NASDAQ: TNXP) , a fully integrated biotech company, announced its inclusion in the Russell 3000® and Russell 2000® Indexes fol ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biotechnology company, today ...

Noble Financial analyst Robert LeBoyer reiterated a Buy rating on GeoVax Labs (GOVX – Research Report) today and set a price target of $10.00. The company’s shares opened toda ...

Tonix Pharmaceuticals Holding Corp. stock could rally with FDA approval for Tonmya targeting fibromyalgia. Click for more on TNXP stock here.

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.

CHATHAM, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biotechnology company with marketed products and a ...

As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to ...